×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| J.B.CHEMICALS & PHARMACEUTICAL | 10538.0 | 1978.7 | 10399.0 | 12.48 | 27,067 | 39.5 |
| Dr. Lal Pathlabs Limited | 6670.0 | 1293.0 | 6407.0 | 15.49 | 26766 | 52.2 |
| PIRAMAL PHARMA LIMITED | 11508.0 | 1131.4 | 9698.8 | 0.85 | 26444 | 306.0 |
J.B. Chemicals & Pharmaceuticals Lt, with Security Code 506943, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 699.1 | 852.6 | 836.8 | 800.1 | 809.2 | 952.3 | 955.8 | 913.5 | 901.3 | 1,039.9 |
| Expenses | 537.7 | 617.8 | 601.9 | 585.4 | 614.2 | 678.9 | 687.6 | 668.1 | 670.4 | 746.8 |
| Operating Profit | 161.4 | 234.8 | 234.8 | 214.7 | 195.1 | 273.4 | 268.2 | 245.4 | 231.0 | 293.1 |
| OPM % | 23.09% | 27.54% | 28.07% | 26.83% | 24.1% | 28.71% | 28.06% | 26.86% | 25.63% | 28.19% |
| Other Income | 3.3 | 5.1 | 6.8 | 6.6 | 16.1 | 5.2 | 8.9 | 7.2 | 13.5 | 13.9 |
| Interest | 12.3 | 11.2 | 9.5 | 11.5 | 8.3 | 4.3 | 2.0 | 1.9 | 0.9 | 0.7 |
| Depreciation | 30.6 | 30.7 | 31.5 | 33.4 | 39.7 | 40.0 | 40.9 | 41.2 | 44.4 | 41.4 |
| Profit before tax | 121.9 | 198.1 | 200.7 | 176.4 | 163.1 | 234.2 | 234.2 | 209.5 | 199.2 | 265.0 |
| Tax % | -27.3% | -27% | -27.8% | -27.5% | -22.8% | -26% | -26.1% | -25.4% | -24.8% | 25.3% |
| Net Profit | 88.7 | 144.6 | 145.0 | 127.9 | 125.9 | 173.2 | 173.1 | 156.4 | 149.8 | 197.9 |
| EPS in Rs | 11.33 | 18.44 | 9.19 | 8.11 | 7.96 | 10.94 | 10.92 | 9.87 | 0 | 12.48 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 792.7 | 762.3 | 896.2 | 881.7 | 844.5 | 861.7 | 1,004.4 | 1,000.6 | 963.5 | 949.5 |
| Expenses | 617.9 | 598.7 | 664.1 | 638.2 | 621.4 | 663.6 | 724.0 | 730.1 | 709.0 | 723.0 |
| Operating Profit | 174.8 | 163.6 | 232.1 | 243.5 | 223.1 | 198.1 | 280.4 | 270.5 | 254.5 | 226.5 |
| OPM % | 22.05% | 21.47% | 25.9% | 27.62% | 26.42% | 22.99% | 27.91% | 27.04% | 26.42% | 23.85% |
| Other Income | 3.1 | 4.6 | 5.6 | 7.7 | 7.4 | 16.6 | 5.9 | 10.0 | 8.0 | 14.5 |
| Interest | 8.3 | 14.0 | 12.1 | 10.4 | 12.5 | 9.4 | 5.6 | 2.1 | 2.6 | 1.5 |
| Depreciation | 28.4 | 31.8 | 31.4 | 32.2 | 34.0 | 40.7 | 40.8 | 41.9 | 41.9 | 46.4 |
| Profit before tax | 141.2 | 122.5 | 194.3 | 208.7 | 184.0 | 164.6 | 239.8 | 236.5 | 218.0 | 193.1 |
| Tax % | -24.9% | -28.4% | -26.8% | -27.8% | -27.4% | -23.4% | -26.3% | -26.2% | -25.5% | -24.5% |
| Net Profit | 106.1 | 87.6 | 142.3 | 150.6 | 133.6 | 126.2 | 176.8 | 174.6 | 162.5 | 145.7 |
| EPS in Rs | 13.57 | 11.19 | 18.14 | 9.54 | 8.46 | 8.06 | 11.17 | 11 | 10.24 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 19% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 21% |
| 3 Years: | 25% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 39% |
| 3 Years: | 29% |
| 1 Year: | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 21% |
| 3 Years: | 23% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 39% |
| 3 Years: | 29% |
| 1 Year: | 0% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|